Format

Send to

Choose Destination
Clin Exp Immunol. 2017 Jun;188(3):437-443. doi: 10.1111/cei.12946. Epub 2017 Mar 16.

Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration.

Author information

1
School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham, NG7 2UH, UK.
2
Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt.
3
UCB Celltech, Slough, SL1 3WE, UK.
4
Public Health England, Salisbury, SP4, OJG, UK.
5
Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, UK.
6
Immunomodulation Research Group, Dublin City University, Dublin 9, Ireland.
7
Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, LS1 3EX, UK.
8
NIHR Biomedical Research Unit in Gastrointestinal and Liver Diseases, Nottingham University and the University of Nottingham, Nottingham, NG7 2UH, UK.

Abstract

The prevalence of serum antibodies against Clostridium difficile (CD) toxins A and B in healthy populations have prompted interest in evaluating the therapeutic activity of intravenous immunoglobulin (IVIg) in individuals experiencing severe or recurrent C. difficile infection (CDI). Despite some promising case reports, a definitive clinical role for IVIg in CDI remains unclear. Contradictory results may be attributed to a lack of consensus regarding optimal dose, timing of administration and patient selection as well as variability in specific antibody content between commercial preparations. The purpose of this study was to investigate retrospectively the efficacy of three commercial preparations of IVIg for treating severe or recurrent CDI. In subsequent mechanistic studies using protein microarray and toxin neutralization assays, all IVIg preparations were analysed for specific binding and neutralizing antibodies (NAb) to CD antigens in vitro and the presence of anti-toxin NAbs in vivo following IVIg infusion. A therapeutic response to IVIg was observed in 41% (10 of 17) of the CDI patients. Significant variability in multi-isotype specific antibodies to a 7-plex panel of CD antigens and toxin neutralization efficacies were observed between IVIg preparations and also in patient sera before and after IVIg administration. These results extend our current understanding of population immunity to CD and support the inclusion of surface layer proteins and binary toxin antigens in CD vaccines. Future strategies could enhance IVIg treatment response rates by using protein microarray to preselect donor plasma/serum with the highest levels of anti-CD antibodies and/or anti-toxin neutralizing capacities prior to fractionation.

KEYWORDS:

Clostridium difficile; antibodies; intravenous immunoglobulin

PMID:
28213939
PMCID:
PMC5422716
DOI:
10.1111/cei.12946
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center